Anteris Technologies Ltd
Anteris Technologies Ltd (AVR.AX) Stock Competitors & Peer Comparison
See (AVR.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AVR.AX | A$5.05 | -1.56% | 187.5M | -0.98 | -A$5.32 | N/A |
| COH.AX | A$311.67 | -2.15% | 20.4B | 55.28 | A$5.65 | +1.73% |
| PNV.AX | A$1.21 | -6.20% | 853.2M | 123.50 | A$0.01 | N/A |
| EBR.AX | A$1.34 | -4.96% | 522.1M | -7.00 | -A$0.20 | N/A |
| IMR.AX | A$1.21 | -1.22% | 329.6M | -6.10 | -A$0.20 | N/A |
| AVH.AX | A$1.69 | +1.20% | 224.1M | -2.54 | -A$0.67 | N/A |
| ARX.AX | A$0.61 | -3.17% | 220.8M | -64.00 | -A$0.01 | N/A |
| SOM.AX | A$0.78 | -4.91% | 180.5M | -16.70 | -A$0.05 | N/A |
| EMV.AX | A$1.74 | +0.00% | 148.8M | -24.86 | -A$0.07 | N/A |
| 4DX.AX | A$0.36 | +47.92% | 142M | -2.77 | -A$0.11 | N/A |
Stock Comparison
AVR.AX vs COH.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, COH.AX has a market cap of 20.4B. Regarding current trading prices, AVR.AX is priced at A$5.05, while COH.AX trades at A$311.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas COH.AX's P/E ratio is 55.28. In terms of profitability, AVR.AX's ROE is -2.19%, compared to COH.AX's ROE of +0.20%. Regarding short-term risk, AVR.AX is more volatile compared to COH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check COH.AX's competition here
AVR.AX vs PNV.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, PNV.AX has a market cap of 853.2M. Regarding current trading prices, AVR.AX is priced at A$5.05, while PNV.AX trades at A$1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas PNV.AX's P/E ratio is 123.50. In terms of profitability, AVR.AX's ROE is -2.19%, compared to PNV.AX's ROE of +0.08%. Regarding short-term risk, AVR.AX is more volatile compared to PNV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check PNV.AX's competition here
AVR.AX vs EBR.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, EBR.AX has a market cap of 522.1M. Regarding current trading prices, AVR.AX is priced at A$5.05, while EBR.AX trades at A$1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas EBR.AX's P/E ratio is -7.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EBR.AX's ROE of -1.51%. Regarding short-term risk, AVR.AX is more volatile compared to EBR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check EBR.AX's competition here
AVR.AX vs IMR.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, IMR.AX has a market cap of 329.6M. Regarding current trading prices, AVR.AX is priced at A$5.05, while IMR.AX trades at A$1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas IMR.AX's P/E ratio is -6.10. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IMR.AX's ROE of +4.30%. Regarding short-term risk, AVR.AX is more volatile compared to IMR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check IMR.AX's competition here
AVR.AX vs AVH.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, AVH.AX has a market cap of 224.1M. Regarding current trading prices, AVR.AX is priced at A$5.05, while AVH.AX trades at A$1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas AVH.AX's P/E ratio is -2.54. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AVH.AX's ROE of -0.40%. Regarding short-term risk, AVR.AX is less volatile compared to AVH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check AVH.AX's competition here
AVR.AX vs ARX.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, ARX.AX has a market cap of 220.8M. Regarding current trading prices, AVR.AX is priced at A$5.05, while ARX.AX trades at A$0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas ARX.AX's P/E ratio is -64.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ARX.AX's ROE of -0.04%. Regarding short-term risk, AVR.AX is more volatile compared to ARX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check ARX.AX's competition here
AVR.AX vs SOM.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, SOM.AX has a market cap of 180.5M. Regarding current trading prices, AVR.AX is priced at A$5.05, while SOM.AX trades at A$0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas SOM.AX's P/E ratio is -16.70. In terms of profitability, AVR.AX's ROE is -2.19%, compared to SOM.AX's ROE of -0.13%. Regarding short-term risk, AVR.AX is less volatile compared to SOM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check SOM.AX's competition here
AVR.AX vs EMV.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, EMV.AX has a market cap of 148.8M. Regarding current trading prices, AVR.AX is priced at A$5.05, while EMV.AX trades at A$1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas EMV.AX's P/E ratio is -24.86. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EMV.AX's ROE of -0.36%. Regarding short-term risk, AVR.AX is more volatile compared to EMV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check EMV.AX's competition here
AVR.AX vs 4DX.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, 4DX.AX has a market cap of 142M. Regarding current trading prices, AVR.AX is priced at A$5.05, while 4DX.AX trades at A$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas 4DX.AX's P/E ratio is -2.77. In terms of profitability, AVR.AX's ROE is -2.19%, compared to 4DX.AX's ROE of -0.60%. Regarding short-term risk, AVR.AX is less volatile compared to 4DX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check 4DX.AX's competition here
AVR.AX vs CYC.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, CYC.AX has a market cap of 115.6M. Regarding current trading prices, AVR.AX is priced at A$5.05, while CYC.AX trades at A$0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas CYC.AX's P/E ratio is -8.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CYC.AX's ROE of -0.29%. Regarding short-term risk, AVR.AX is less volatile compared to CYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check CYC.AX's competition here
AVR.AX vs IPD.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, IPD.AX has a market cap of 95.3M. Regarding current trading prices, AVR.AX is priced at A$5.05, while IPD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas IPD.AX's P/E ratio is -4.70. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IPD.AX's ROE of -0.58%. Regarding short-term risk, AVR.AX is more volatile compared to IPD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check IPD.AX's competition here
AVR.AX vs CMP.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, CMP.AX has a market cap of 68.2M. Regarding current trading prices, AVR.AX is priced at A$5.05, while CMP.AX trades at A$0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas CMP.AX's P/E ratio is -17.75. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CMP.AX's ROE of -0.09%. Regarding short-term risk, AVR.AX is more volatile compared to CMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check CMP.AX's competition here
AVR.AX vs CSX.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, CSX.AX has a market cap of 59.9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while CSX.AX trades at A$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas CSX.AX's P/E ratio is -38.25. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CSX.AX's ROE of -0.08%. Regarding short-term risk, AVR.AX is more volatile compared to CSX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check CSX.AX's competition here
AVR.AX vs MX1.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, MX1.AX has a market cap of 53.4M. Regarding current trading prices, AVR.AX is priced at A$5.05, while MX1.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas MX1.AX's P/E ratio is -4.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to MX1.AX's ROE of -1.06%. Regarding short-term risk, AVR.AX is more volatile compared to MX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check MX1.AX's competition here
AVR.AX vs RSH.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, RSH.AX has a market cap of 52M. Regarding current trading prices, AVR.AX is priced at A$5.05, while RSH.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas RSH.AX's P/E ratio is -3.30. In terms of profitability, AVR.AX's ROE is -2.19%, compared to RSH.AX's ROE of -2.03%. Regarding short-term risk, AVR.AX is less volatile compared to RSH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check RSH.AX's competition here
AVR.AX vs EYE.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, EYE.AX has a market cap of 41.2M. Regarding current trading prices, AVR.AX is priced at A$5.05, while EYE.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas EYE.AX's P/E ratio is -3.62. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EYE.AX's ROE of -0.44%. Regarding short-term risk, AVR.AX is less volatile compared to EYE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check EYE.AX's competition here
AVR.AX vs LBT.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, LBT.AX has a market cap of 29.9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while LBT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas LBT.AX's P/E ratio is -0.42. In terms of profitability, AVR.AX's ROE is -2.19%, compared to LBT.AX's ROE of -1.50%. Regarding short-term risk, AVR.AX is more volatile compared to LBT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check LBT.AX's competition here
AVR.AX vs OSL.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, OSL.AX has a market cap of 20.9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while OSL.AX trades at A$1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas OSL.AX's P/E ratio is -0.62. In terms of profitability, AVR.AX's ROE is -2.19%, compared to OSL.AX's ROE of -1.97%. Regarding short-term risk, AVR.AX is more volatile compared to OSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check OSL.AX's competition here
AVR.AX vs NTI.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, NTI.AX has a market cap of 19.9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while NTI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas NTI.AX's P/E ratio is -1.90. In terms of profitability, AVR.AX's ROE is -2.19%, compared to NTI.AX's ROE of -1.34%. Regarding short-term risk, AVR.AX is less volatile compared to NTI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check NTI.AX's competition here
AVR.AX vs CDX.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, CDX.AX has a market cap of 18.7M. Regarding current trading prices, AVR.AX is priced at A$5.05, while CDX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas CDX.AX's P/E ratio is -0.57. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CDX.AX's ROE of -2.72%. Regarding short-term risk, AVR.AX is less volatile compared to CDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check CDX.AX's competition here
AVR.AX vs AT1.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, AT1.AX has a market cap of 15M. Regarding current trading prices, AVR.AX is priced at A$5.05, while AT1.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas AT1.AX's P/E ratio is -1.90. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AT1.AX's ROE of -0.74%. Regarding short-term risk, AVR.AX is less volatile compared to AT1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check AT1.AX's competition here
AVR.AX vs CBL.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, CBL.AX has a market cap of 13.3M. Regarding current trading prices, AVR.AX is priced at A$5.05, while CBL.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas CBL.AX's P/E ratio is -1.50. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CBL.AX's ROE of -1.09%. Regarding short-term risk, AVR.AX is less volatile compared to CBL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check CBL.AX's competition here
AVR.AX vs TRU.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, TRU.AX has a market cap of 12M. Regarding current trading prices, AVR.AX is priced at A$5.05, while TRU.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas TRU.AX's P/E ratio is -1.60. In terms of profitability, AVR.AX's ROE is -2.19%, compared to TRU.AX's ROE of -0.69%. Regarding short-term risk, AVR.AX is more volatile compared to TRU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check TRU.AX's competition here
AVR.AX vs RNO.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, RNO.AX has a market cap of 11.5M. Regarding current trading prices, AVR.AX is priced at A$5.05, while RNO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas RNO.AX's P/E ratio is -1.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to RNO.AX's ROE of +15.91%. Regarding short-term risk, AVR.AX is more volatile compared to RNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check RNO.AX's competition here
AVR.AX vs HMD.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, HMD.AX has a market cap of 10.5M. Regarding current trading prices, AVR.AX is priced at A$5.05, while HMD.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas HMD.AX's P/E ratio is -1.20. In terms of profitability, AVR.AX's ROE is -2.19%, compared to HMD.AX's ROE of -2.84%. Regarding short-term risk, AVR.AX is more volatile compared to HMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check HMD.AX's competition here
AVR.AX vs ADR.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, ADR.AX has a market cap of 9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while ADR.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas ADR.AX's P/E ratio is -0.12. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ADR.AX's ROE of -2.87%. Regarding short-term risk, AVR.AX is more volatile compared to ADR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check ADR.AX's competition here
AVR.AX vs IRX.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, IRX.AX has a market cap of 9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while IRX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas IRX.AX's P/E ratio is -4.20. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IRX.AX's ROE of +17.09%. Regarding short-term risk, AVR.AX is less volatile compared to IRX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check IRX.AX's competition here
AVR.AX vs UBI.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, UBI.AX has a market cap of 6.6M. Regarding current trading prices, AVR.AX is priced at A$5.05, while UBI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas UBI.AX's P/E ratio is -0.55. In terms of profitability, AVR.AX's ROE is -2.19%, compared to UBI.AX's ROE of -0.77%. Regarding short-term risk, AVR.AX is more volatile compared to UBI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check UBI.AX's competition here
AVR.AX vs OVN.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, OVN.AX has a market cap of 4.8M. Regarding current trading prices, AVR.AX is priced at A$5.05, while OVN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas OVN.AX's P/E ratio is -0.40. In terms of profitability, AVR.AX's ROE is -2.19%, compared to OVN.AX's ROE of -0.80%. Regarding short-term risk, AVR.AX is more volatile compared to OVN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check OVN.AX's competition here
AVR.AX vs ALT.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, ALT.AX has a market cap of 4.6M. Regarding current trading prices, AVR.AX is priced at A$5.05, while ALT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas ALT.AX's P/E ratio is N/A. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ALT.AX's ROE of -2.31%. Regarding short-term risk, AVR.AX is more volatile compared to ALT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check ALT.AX's competition here
AVR.AX vs VTI.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, VTI.AX has a market cap of 3.7M. Regarding current trading prices, AVR.AX is priced at A$5.05, while VTI.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas VTI.AX's P/E ratio is -0.55. In terms of profitability, AVR.AX's ROE is -2.19%, compared to VTI.AX's ROE of -0.57%. Regarding short-term risk, AVR.AX is more volatile compared to VTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check VTI.AX's competition here
AVR.AX vs AMT.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, AMT.AX has a market cap of 3.5M. Regarding current trading prices, AVR.AX is priced at A$5.05, while AMT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas AMT.AX's P/E ratio is -1.45. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AMT.AX's ROE of -11.52%. Regarding short-term risk, AVR.AX is less volatile compared to AMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.Check AMT.AX's competition here
AVR.AX vs UCM.AX Comparison August 2025
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 187.5M. In comparison, UCM.AX has a market cap of 2.9M. Regarding current trading prices, AVR.AX is priced at A$5.05, while UCM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -0.98, whereas UCM.AX's P/E ratio is -1.10. In terms of profitability, AVR.AX's ROE is -2.19%, compared to UCM.AX's ROE of -0.96%. Regarding short-term risk, AVR.AX is more volatile compared to UCM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.Check UCM.AX's competition here